Many attempts have been made recently to discover PD-1 inhibitors for treating different kinds of tumors, including but not limited to advanced melanoma and non-small cell lung cancer (NSCLC). The clinical data have shown that these antibodies targeting PD-1 and its ligand PD-L1 can block the activation of T cells and induce anti-tumor activities to improve patients' outcomes in the clinic.